Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Survival after squamous recurrence may be unaffected by immune status
Key clinical point: Patients who have recurrence of cutaneous squamous cell cancer of the head and neck (cSCC-HN) tend to have poor outcomes regardless of immune status.
Major finding: Patients with recurrent disease who were not amenable to surgical salvage had a median overall survival of 4.7 months, compared with 26.1 months for patients who were amenable to surgical salvage.
Study details: A retrospective analysis of 205 patients with cutaneous squamous cell cancer of the head and neck (cSCC-HN).
Disclosures: The investigators reported clinical trial support from Genentech, Merck, and Bristol-Myers Squibb.
Sun et al. JAMA Dermatol. 2019 Feb 27. doi: 10.1001/jamadermatol.2018.5453.